Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Clement

Showing results (411-420 of 444) with videos related to

Pageof 45
Sort By:
Nature Medicine|October 19, 2023
BrainStorm: a multicenter international study to tackle CNS metastases in solid tumorsDiogo Martins-Branco, Guilherme Nader-Marta, Andrea Gombos, et al.
BMJ (Clinical Research Ed.)|October 31, 2009
Implementation of the Canadian C-Spine Rule: prospective 12 centre cluster randomised trialIan G Stiell, Catherine M Clement, Jeremy Grimshaw, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 19, 2018
Activity and safety of afatinib in a window preoperative EORTC study in patients with squamous cell carcinoma of the head and neck (SCCHN)J-P Machiels, P Bossi, J Menis, et al.
The Lancet. Oncology|April 21, 2015
Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trialJean-Pascal H Machiels, Robert I Haddad, Jérôme Fayette, et al.
Oral Oncology|August 27, 2019
Afatinib as second-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Subgroup analyses of treatment adherence, safety and mode of afatinib administration in the LUX-Head and Neck 1 trialRobert Haddad, Joel Guigay, Ulrich Keilholz, et al.
Lancet (London, England)|February 3, 2020
Electrical versus pharmacological cardioversion for emergency department patients with acute atrial fibrillation (RAFF2): a partial factorial randomised trialIan G Stiell, Marco L A Sivilotti, Monica Taljaard, et al.
The New England Journal of Medicine|November 16, 2017
Lomustine and Bevacizumab in Progressive GlioblastomaWolfgang Wick, Thierry Gorlia, Martin Bendszus, et al.
Neuro-Oncology Advances|July 10, 2020
EGFR mutations are associated with response to depatux-m in combination with temozolomide and result in a receptor that is hypersensitive to ligandYouri Hoogstrate, Wies Vallentgoed, Johan M Kros, et al.
Journal of Medical Genetics|October 30, 2007
Hirschsprung disease, associated syndromes and genetics: a reviewJ Amiel, E Sproat-Emison, M Garcia-Barcelo, et al.
European Journal of Cancer (Oxford, England : 1990)|December 22, 2018
Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapyDan P Zandberg, Alain P Algazi, Antonio Jimeno, et al.
Pageof 45

Showing results (411-420 of 444) with videos related to

Sort By:
Pageof 45
Nature Medicine|October 19, 2023
BrainStorm: a multicenter international study to tackle CNS metastases in solid tumorsDiogo Martins-Branco, Guilherme Nader-Marta, Andrea Gombos, et al.
BMJ (Clinical Research Ed.)|October 31, 2009
Implementation of the Canadian C-Spine Rule: prospective 12 centre cluster randomised trialIan G Stiell, Catherine M Clement, Jeremy Grimshaw, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 19, 2018
Activity and safety of afatinib in a window preoperative EORTC study in patients with squamous cell carcinoma of the head and neck (SCCHN)J-P Machiels, P Bossi, J Menis, et al.
The Lancet. Oncology|April 21, 2015
Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trialJean-Pascal H Machiels, Robert I Haddad, Jérôme Fayette, et al.
Oral Oncology|August 27, 2019
Afatinib as second-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Subgroup analyses of treatment adherence, safety and mode of afatinib administration in the LUX-Head and Neck 1 trialRobert Haddad, Joel Guigay, Ulrich Keilholz, et al.
Lancet (London, England)|February 3, 2020
Electrical versus pharmacological cardioversion for emergency department patients with acute atrial fibrillation (RAFF2): a partial factorial randomised trialIan G Stiell, Marco L A Sivilotti, Monica Taljaard, et al.
The New England Journal of Medicine|November 16, 2017
Lomustine and Bevacizumab in Progressive GlioblastomaWolfgang Wick, Thierry Gorlia, Martin Bendszus, et al.
Neuro-Oncology Advances|July 10, 2020
EGFR mutations are associated with response to depatux-m in combination with temozolomide and result in a receptor that is hypersensitive to ligandYouri Hoogstrate, Wies Vallentgoed, Johan M Kros, et al.
Journal of Medical Genetics|October 30, 2007
Hirschsprung disease, associated syndromes and genetics: a reviewJ Amiel, E Sproat-Emison, M Garcia-Barcelo, et al.
European Journal of Cancer (Oxford, England : 1990)|December 22, 2018
Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapyDan P Zandberg, Alain P Algazi, Antonio Jimeno, et al.
Pageof 45